Our data suggested that PORT administered using the 3D-CRT technique following our institutional standard CTV delineation guideline resulted in promising outcomes regarding local control and survival improvements for completely resected stage IIIA(N2) NSCLC patients, after controlling for the confounding effect of subsequent EGFR-TKI therapy in the OS analysis. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.